Actinium Pharmaceuticals (ATNM) Return on Equity (2021 - 2025)
Actinium Pharmaceuticals (ATNM) has disclosed Return on Equity for 6 consecutive years, with 1.0% as the latest value for Q3 2024.
- On a quarterly basis, Return on Equity rose 7.0% to 1.0% in Q3 2024 year-over-year; TTM through Sep 2024 was 1.0%, a 7.0% increase, with the full-year FY2023 number at 0.95%, down 46.0% from a year prior.
- Return on Equity was 1.0% for Q3 2024 at Actinium Pharmaceuticals, down from 0.97% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.19% in Q2 2021 to a low of 1.25% in Q4 2023.
- A 4-year average of 0.74% and a median of 0.65% in 2022 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: crashed -75bps in 2023, then grew 7bps in 2024.
- Actinium Pharmaceuticals' Return on Equity stood at 0.54% in 2021, then rose by 9bps to 0.5% in 2022, then plummeted by -152bps to 1.25% in 2023, then grew by 20bps to 1.0% in 2024.
- Per Business Quant, the three most recent readings for ATNM's Return on Equity are 1.0% (Q3 2024), 0.97% (Q2 2024), and 1.17% (Q1 2024).